Portland Press, as the Biochemical Society’s publisher, works in partnership with researchers, institutions, and funders to share knowledge and advance the molecular biosciences.
Publishing world-leading research and reviews across our portfolio of seven journals, it returns all profits to the life science community in support of our Society’s charitable activities.
Authors from the institutions listed below are able to publish immediately to open access on the publisher's platform once the article has been accepted.
From 2022, the following institutions will also participate in this agreement:
Biochemical Society journals included in the CAUL Portland Read and Publish Agreement include:
Corresponding authors from institutions listed under 'Participating institutions' may publish immediately to open access on the publisher's platform once the article has been accepted, with no transactional APCs.
Submit your article via the publisher's platform.
You will be recognised as being eligible for open access publishing with no transactional APCs when you select your institution in the submission system.
Further information on the agreement and the Read & Publish process, including FAQs for authors, is available on the publisher's website.
The agreement is for a three-year pilot (2020-2022) on an opt-in basis.
This agreement provides unlimited access to all five hybrid journals including all current and previous content. The five hybrid journals are:
Text and data mining is also allowed.
The other two journals, Bioscience Reports and Neuronal Signaling, are fully open access.
Using Rightslink, library staff may set up an institutional account to
The publisher submits open access articles and metadata to all relevant third-party repositories, such as PubMed Central, Europe PubMed Central, Google Scholar (all journals, crawled by Google), CAS, Web of Science, Scopus, and Embase.